



Advances in Molecular Mechanisms of Head and Neck Cancers

Guest Editors:

Prof. Dr. Chih-Yen Chien

1. Department of Otolaryngology,
Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan
2. College of Medicine, Chang
Gung University, Taoyuan City,
Taiwan

Prof. Dr. Pei-Jen Lou

Department of Otolaryngology
Head and Neck Surgery, National
Taiwan University Hospital,
Taipei, Taiwan

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editors

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) ranks as the world's sixth most common cancer among male patients according to the GLOBOCAN 2020 database. The clinical outcomes for advanced-stage tumors remain unsatisfactory. Cisplatin, 5-FU and docetaxol are the most common chemotherapy agents for HNSCC; however, chemo-resistance is currently a major problem among patients with recurrent and metastatic disease (R/M disease). Checkpoint inhibitors can be applied for salvage in R/M disease according to the clinical trials Checkmate-141 and Keynote-048. Clinically, some patients demonstrate responses to checkpoint inhibitors, but a significant number of patients show progressive disease. There are several unique molecular features in these advanced, chemoresistant tumors, and some tumors are responsive to checkpoint inhibitors. For this Special Issue, we welcome submissions focusing on these molecular characters and highlighting new treatment strategies for HNSCC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)